We previously reported that Sp1-dependent Cdc2 gene expression is inhibited by tetra-O-methyl nordihydroguaiaretic acid (M 4N) and that M 4N is likely responsible for causing growth arrest in M4N-treated transformed C3 cells. Here, we show that after M 4N treatment and cell-cycle arrest, expression of the Sp1-dependent survivin gene, a member of the inhibitor of apoptosis family, is also suppressed, and the mitochondrial apoptotic pathway is activated. To confirm that inhibition of Cdc2 and survivin gene expression is necessary for M 4N-induced growth arrest and apoptosis, we tested the effect of adding Cdc2 and survivin back to M 4N-treated cells. Cell division was transiently restored in the presence of M 4N after transfection of an exogenous Cdc2 gene copy under the control of the Sp1-independent cytomegalovirus promoter. Caspase-3 activation was also reduced by 50% and 75% in transiently and stably survivin-transfected C3 cells, respectively. The results suggest that M 4N induces growth arrest and apoptosis by suppressing Cdc2 and survivin expression, which constitutes the cellular basis of its antitumoric action.
C
ancers are diverse and heterogeneous, affected by both genetic and epigenetic alterations. Yet, all cancers display deregulated cell proliferation and suppressed apoptosis (1) . Development of anticancer drugs that can selectively target defects in key pathways controlling these two processes and eliminate transformed cells without damaging both regenerating and differentiated host tissues has since become the main challenges facing all oncologists today.
Our laboratory has been focusing on finding small organic compounds that can selectively arrest growth and induce apoptosis of cancer cells with minimal toxicity to normal tissues. We found earlier that an anti-HIV proviral transcriptional inhibitor, tetra-O-methyl nordihydroguaiaretic acid (M 4 N) (2, 3) , was able to cause growth arrest of a variety of transformed human and mouse cells in culture and in mice (4). As we have previously reported that 3-O-methyl-NDGA (Mal.4) inhibited HIV proviral transcription by specifically blocking Sp1 transcriptional factor to bind HIV long-terminal repeats (5), M 4 N, a DNA major groove binder for G͞C-rich sequence, was found to block cell-cycle progression at G 2 ͞M by inhibiting the transcription of an Sp1-dependent gene coding for cyclin-dependent kinase (Cdc2). Intratumoral and i.p. injection of M 4 N was exceedingly effective in eliminating C3 cells in mice (4) and murine melanoma cells (6) , respectively. At the 6th International Conference on Head and Neck Cancer (August 2004, Washington, DC), it was presented that clinically evident tumor necrosis was also observed in head and neck cancer patients following intratumoral administration of M 4 N. High concentrations of M 4 N in long-term feeding experiment also caused no apparent toxicities to mice (7) . Reasons for such differential cytocidal effects of M 4 N toward tumors vs. normal adult tissues are not clear at the present time. Molecular studies reported in the present communication may provide some insights on this matter.
It is well known that apoptosis is a regulated physiological process leading to cell death. It is characterized by cell shrinkage, membrane blebbing, and nuclear condensation, mediated by the actions of caspases. Two apoptotic pathways have been described: the death receptor and the mitochondrial pathways, each of which leads to the activation of the downstream effector caspases 3 and 7, which dismantle the cell (8) .
There are also genes that regulate the apoptotic pathways. These include survivin gene whose product is an inhibitor of apoptosis protein that has been implicated in integrating cell division and apoptosis (9) . Survivin is overexpressed in most cancers but undetectable in most terminally differentiated normal adult tissues (10, 11) , with the exception of thymocytes (10) , CD34 ϩ stem cells (12) , and basal colonic epithelial cells (13) . Means of targeting survivin such as antisense and ribozyme have been exploited to induce apoptosis in cancer cells (14) (15) (16) . The expression of survivin is G 2 ͞M cell-cycle specific and is highly Sp1-dependent, with transcriptional activity requiring two critical Sp1 sites (17, 18) . In the present study, we show that M 4 N not only can inhibit Cdc2 gene expression, but is also an effective inhibitor for transcription of Sp1-dependent survivin gene. Apoptosis was induced when survivin production was inhibited in M 4 N-treated C3 cells. Such inhibitory effects were found to be remarkably specific for transcriptions of Sp1-regulated endogenous survivin and Cdc2 genes. For example, both cell arrest and caspase-3 activity can be substantially reversed in M 4 N-treated C3 cells when transfected with exogenous Cdc2 and survivin gene constructed with an Sp1-independent cytomegalovirus (CMV) promoter, respectively.
The histology of skin, spine, and muscle tissues from mice injected s.c. with M 4 N dissolved in DMSO did not differ from those tissues injected with DMSO and uninjected normal tissues, while inducing apoptosis in the targeted tumor cells (19) . Because there is no survivin expression, M 4 N-induced apoptosis is perhaps inoperative in normal tissues. Yet M 4 N functions fully in suppressing growth and causing programmed cell death in transformed cells by its dual inhibitory effect on expression of two cell-cycle related genes, Cdc2 and survivin. Development of M 4 N as a tumor-selective, anticancer agent for humans seems to be worthy of consideration.
Terminal Deoxynucleotidyltransferase-Mediated dUTP Nick End Labeling Assay. C3 cells were grown on coverslips followed by M 4 N treatment for 3 days. Labeling of fragmented DNA was carried out with the Cell Death Detection kit (Roche Diagnostics) according to the manufacturer's protocol. The cells were analyzed on a Zeiss Axioplan microscope, and apoptotic cells in three random fields were scored.
Antibodies, Western Blotting, and Kinase Assay. The antibodies used for Western blotting analysis were the antibodies against mouse caspase-3, cyclin B, and survivin (Santa Cruz Biotechnology), mouse caspase-8 (Pharmingen), mouse caspase-9 and cytochrome c (Cell Signaling Technology, Beverly, MA), and mouse Cdc2 (Oncogene Research Products, Cambridge, MA). Cell lysates were prepared in lysis solution (4) . For Western blots, proteins were analyzed with Western Light Plus Protein Detection kit (Tropix, Bedford, MA). For Cdc2 kinase assay, C3 cells were lysed with cold lysis buffer (10 mM Tris, pH 7.4͞1.0% Triton X-100͞0.5% Nonidet P-40͞150 mM NaCl͞20 mM sodium fluoride, 1ϫ protease inhibitor mixture); 300 g of protein of cell lysate was incubated with 3 g of monoclonal cyclin B1 antibody for 1 h at 4°C with gentle agitation. Protein A͞G agarose pellets were equilibrated with immunoprecipitation (IP) buffer (10 mM Tris, pH 7.4͞1.0% Triton X-100͞0.5% Nonidet P-40͞150 mM NaCl͞20 mM, 1ϫ protease inhibitor mixture) and added to protein extract solutions. Samples were incubated at 4°C overnight, followed by three washes with IP buffer and two washes with kinase buffer (10 mM Tris⅐HCl, pH 7.4͞150 mM NaCl͞10 mM MgCl 2 ͞0.5 mM DTT). Pellets were incubated with 50 l of the kinase buffer containing 25 M ATP, 2.5 Ci of [
32 ␥]ATP (1 Ci ϭ 37 GBq), and 50 g of histone H1 at 37°C for 30 min. Reactions were stopped by the addition of 6ϫ SDS sample buffer and boiling the mixture for 5 min. Proteins were separated on an SDS͞12% PAGE gel. The gel was stained with Coomassie brilliant blue, dried, and exposed to x-ray film.
Cytochrome c Release Assay. C3 cells treated with 1% DMSO or 40 M M 4 N in 1% DMSO for 3 days were harvested. Cytosolic and mitochondrial extracts were prepared. For testing cytochrome c release, a high-quality, well established mitochondrial fractionation procedure was used (21) . The supernatant (cytosol) and pellet (mitochondria) from this fractionation were analyzed by Western blotting.
Caspase-3 Activity Assay. Cells were lysed in 50 mM Hepes (pH 7.4)͞100 mM NaCl͞0.1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS)͞1 mM DTT͞0.1 mM EDTA, and 30 g of protein of cell lysate was added to the assay buffer (50 mM Hepes, pH 7.4͞100 mM NaCl͞0.1% CHAPS͞10 mM DTT͞0.1 mM EDTA͞10% glycerol) in a final volume of 90 l in a 96-well flat bottom plate. The reaction was initiated by the addition of 10 l of 2 mM caspase-3 chromogenic tetrapeptide substrate (Ac-DEVD-pNA) (Calbiochem) and kept at 37°C for 6 h. OD at 405 nm was measured with a 96-well microplate reader.
RT-PCR Analysis. Total RNA was isolated from cultured cells by the guanidinium thiocyanate and phenol method (22) . A 343-bp RT-PCR product was generated by using survivin-specific sense (5Ј-GCATCGCCACCTTCAAGAACTGGCCC-3Ј) and antisense (5Ј-CGGGTAGTCTTTGCAGTCTCTTCAAACTC-3Ј) primers, which detected only survivin 140, the survivin species that possesses the inhibitor of apoptosis protein functions. GAPDH sense (5Ј-GAATCTACTGGCGTCTTCACC-3Ј) and antisense (5Ј-GTCATGAGCCCTTCCACGATGC-3Ј) primers were used to generate a 238-bp RT-PCR product as a control. The RT-PCR products were separated by electrophoresis on a 1.8% agarose gel containing ethidium bromide and photographed. The signal intensities were quantified by SCION IMAGE (Scion, Frederick, MD).
Plasmids and Transfection. Full-length mouse survivin cDNA (kindly provided by E. M. Conway, University of Leuven, Leuven, Belgium) and full-length Cdc2 (generated by RT-PCR of RNA from C3 cells) were subcloned into pcDNA3.1-myc-His or pIRESpuro2 to generate proper expression clones for Cdc2 and survivin under a CMV promoter. Transient transfections were carried out with FuGENE 6 (Roche Applied Science) according to manufacturer's protocol. For the recovery experiment using pIRESpuro2-Cdc2, cells were then incubated with media containing 40 M M 4 N in 1% DMSO for 4 days. Cell viability was assessed by trypan blue exclusion. For the cotransfection experiment, C3 cells were cotransfected with the various cDNA-containing constructs and lacZ in pcDNA3.1-myc-His for 8 h in serum-free media, which were then replaced by complete media containing 40 M M 4 N. After M 4 N treatment, cells were fixed and stained with 5-bromo-4-chloro-3-indolyl ␤-Dgalactoside. Blue cells were scored in 10 random fields for each dish. For the caspase-3 inhibition study, cells were transfected with the Cdc2 and survivin pcDNA3.1-myc-His constructs. After drug treatment with 40 M M 4 N for 3 days, cell lysates were prepared and analyzed for caspase-3 activity as described above. Stable lines were established by transfecting C3 cells with pIRESpuro2-survivin-myc-His and selected in 2.0 g͞ml puromycin. A single clone with maximal expression of survivin was selected to be used in current studies.
Immunofluorescence. Monolayer cultures of C3 cells were fixed with 3% paraformaldehyde in serum-free media for 10 min and then with 3% paraformaldehyde in PBS for 20 min at 4°C, followed by quenching with 50 mM NH 4 Cl-PBS. The fixed cells were blocked for 30 min in PBS containing 1% BSA and 0.075% saponin and incubated with primary antibody for 1 h and then with FITC-conjugated goat anti-rabbit secondary antibody. Coverslips were mounted with VECTASHIELD containing 4Ј,6-diamidino-2-phenylindole (Vector Laboratories) and analyzed on a Zeiss Axioplan microscope.
Results

M4N Induces Apoptosis.
Our previous data on M 4 N showed that it inhibited cell proliferation and induced cell death in several mammalian cell lines (4). Cells undergoing programmed death or apoptosis exhibit characteristic morphological changes, such as DNA cleavage, nuclear condensation, and formation of apoptotic bodies. We used 4Ј,6-diamidino-2-phenylindole staining and the terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling assay to assess these nuclear morphological features in C3 cells treated with 40 M M 4 N for 3 days. In the terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling assay, DNA breaks are labeled by fluorescein nucleotides catalyzed by terminal deoxynucleotidyltransferase (23) . In the M 4 N-treated C3 cells, a significant number of nuclei was extensively fragmented and appeared bright green or light blue with a 4Ј,6-diamidino-2-phenylindole counter stain (Fig.  1A) . Quantitatively, apoptotic cells and the total number of cells were scored in three random fields, and the percentage of apoptotic cells was obtained. As expected, the percentage of apoptotic cells increased with M 4 N concentration (Fig. 1 A) .
To biochemically assay the induction of apoptosis by M 4 N, we measured the activation of caspase-3. C3 cells were treated with M 4 N for 3 days. Caspase-3 activity was quantified using a chromogenic tetrapeptide substrate (Ac-DEVD-pNA). M 4 N treatment resulted in dose-dependent increase in caspase-3 activity (Fig. 1B) , up to an 8.3-fold increase after treatment with 40 M M 4 N. At the higher dosage of 60 M, however, caspase-3 activity was reduced to only 2.2 times more than the control, possibly a reflection of caspase-3 degradation as found for many cellular proteins at advanced stages of apoptosis.
The effect of M 4 N on caspase-3 activation was also assessed by Western blotting using anticaspase-3 antibodies. Caspase-3 is activated by specific proteolytic processing of the 32-kDa procaspase-3 protein to the 20-kDa caspase-3 polypeptide. Western blot analysis of total protein isolated from the treated cells with anti-caspase-3 antibody demonstrates a good correlation between the dose-dependent increase in caspase-3 activity (Fig.  1B) and the appearance of the 20-kDa caspase-3 cleavage product (Fig. 1C) .
We next asked which of the two apoptotic pathways, the death receptor or the mitochondrial pathway, was activated in M 4 Ntreated C3 cells. A same Western blot was probed sequentially with antibodies against caspases 8 and 9, and cyclin B-1, the loading control. It showed that caspase-8 was not activated, whereas caspase-9 was; this was shown by the decreasing levels of procaspase-9 with increasing concentrations of M 4 N, whereas procaspase-8 and cyclin B1 remained constant (Fig. 1D) . Activation of caspase-9 requires the release of cytochrome c into the cytosol from mitochondria. We investigated whether M 4 N treatment caused mitochondria to expel cytochrome c. Cytosolic and mitochondrial extracts from C3 cells treated with DMSO or 40 M M 4 N were separated and then analyzed by Western blotting. In the DMSO-treated cells, cytochrome c remained in the mitochondrial extract, and only very little was present in the cytosolic extract (Fig. 1D, 0 M, lanes M and C) . However, in the M 4 N-treated cells, the mitochondrial pool of cytochrome c was reduced, whereas a significant amount of cytochrome c was present in the cytosol (Fig. 1D, 40 M, lanes M and C) . This was consistent with the activation of caspase-9, suggesting the notion that M 4 N induced the mitochondrial apoptotic pathway.
Down-Regulation of Survivin Expression by M4N Treatment.
Our previous studies showed that M 4 N prevents Sp1 binding to its cognate binding sites in the promoter regions of Sp1-dependent genes (2, 3) . Given that the expression of survivin is Sp1-dependent (17, 18) , and our finding that M 4 N induces caspase-3 activation, we next investigated the effect of M 4 N on survivin gene expression. We performed RT-PCR analysis of survivin mRNA levels in C3 cells. The expression of GAPDH, a nonSp1-dependent housekeeping gene not affected by M 4 N treatment (4), was used for normalization. Treatment with M 4 N for 3 days greatly reduced survivin mRNA levels. For cells treated with 60 M M 4 N for 3 days, expression of survivin mRNA was reduced to Ϸ20% compared with the cells treated with 1% DMSO (Fig. 2A) . Treatment with M 4 N also inhibited survivin protein levels. Western blots of proteins extracted from untreated C3 cells using anti-survivin antibodies showed a 16.5-kDa survivin protein band, whereas cyclin B1 level remained unaffected by the M 4 N treatments (Fig. 2B) . Treatment with M 4 N for 3 days significantly reduced the level of survivin protein in response to increasing M 4 N concentrations, consistent with the activation of caspase-3 and induction of apoptosis in these cells.
During interphase, survivin has been localized in the cell in some studies to the cytoplasm and in others to the nucleus (10, 11, 24, 25) . By using fluorescent antibody staining with antisurvivin antibodies, we observed that survivin was expressed and localized to both subcellular compartments in C3 cells at interphase, although most was dispersed throughout the cytoplasm (Fig. 2C Left) . Consistent with the Western blot results, treatment with 40 M M 4 N for 3 days cleared both nuclear and cytosolic pools of survivin in C3 cells (Fig. 2C Right) .
M4N-Induced Growth Arrest Is Reversible and Correlates with the
Levels of Cdc2 and Cdc2͞Cyclin B Activity in Short Duration. Many therapeutic approaches that induce cell growth arrest are irre- (Fig. 3A) . As the time course continued, the growth rate of these cells continued to rise. Similar growth recovery was seen in a separate experiment in which the human cervical cancer cell line, C33a, was treated with M 4 N, as above, and then reseeded at low density in a colony-forming assay (19) . All cells retained greater than 95% viability during these experiments. We next examined the Cdc2 protein levels from cells incubated with 20 or 40 M M 4 N for 3 days followed by incubation in fresh media containing either 1% DMSO or M 4 N in 1% DMSO for 3 more days. Cells from which the drug was removed (Fig. 3B, 20D and 40D ) produced normal levels of Cdc2 protein as compared to cells grown with just 1% DMSO in the media throughout (DMSO). However, cells incubated with M 4 N for 6 days (Fig. 3B , lanes 20 and 40) expressed much less Cdc2. In all samples, the levels of cyclin B remained equivalent. Such reduction of Cdc2 expression should also correlate with Cdc2 kinase activity. Indeed, similar recovery of Cdc2 kinase activities from M 4 N treatment was observed (Fig. 3B) .
M4N Treatment Induced a Reversible Shift of Cdc2 Protein from the
Nucleus to the Cytoplasm. Active Cdc2 protein is primarily found in the nucleus of cells, where it performs its role in myriad processes including histone phosphorylation. When the active protein is not needed, it is transferred to the cytoplasm for degradation (26) . To examine the impact of M 4 N on Cdc2 localization, we incubated C3 cells for 3 days in media containing 1% DMSO or 40 M M 4 N. Following this treatment, the media were removed, and the cells were washed twice with PBS. Half of the drug-exposed cells were then switched to media containing only 1% DMSO, whereas the other half received fresh media containing 40 M M 4 N. As expected, Cdc2 was primarily found in the nucleus of C3 cells treated with 1% DMSO (Fig. 3C Left) . Interestingly, residual Cdc2 protein of cells treated with 40 M M 4 N for 6 days was almost entirely located in the cytoplasm (Fig.  3C Center) . Moreover, cells that had received 1% DMSO and 40 M M 4 N for 3 days followed by 3 days in media without M 4 N showed a full recovery of Cdc2 in the nucleus (Fig. 3C Right) . Additional experiments (19) determined that the cytoplasmic localization of residual Cdc2 in M 4 N-treated cells was apparent after as little as 48 h, indicating that the Cdc2 localization seen in Fig. 3C Right may result from newly synthesized Cdc2 and from those recovered from the state of Cdc2 localization observed in Fig. 3C Center. Thus, when M 4 N-treated cells are returned to normal media, Cdc2 is mainly localized in the nucleus.
Reduction of M4N-Induced Caspase-3 Activity by Cdc2 and Survivin
Overexpression. We next sought to investigate whether an exogenous gene subcloned in the pcDNA3.1 plasmid, a Sp1-unregulated CMV promoter, could be expressed in transfected C3 cells in the presence of M 4 N. Survivin cDNA was subcloned into pcDNA3.1-myc-His, and expression of CMV-survivin was examined. In the absence of M 4 N, cells not transfected and transfected with the empty vector only expressed endogenous survivin as expected. Cells transfected with survivin-myc-His expressed both the endogenous and the larger tagged survivin. After treatment with 40 M M 4 N for 3 days, the endogenous survivin protein was no longer detectable. However, the same M 4 N treatment did not inhibit the overexpression of survivinmyc-His in cells transfected with CMV-survivin (Fig. 4A) .
If inhibition of survivin synthesis was indeed to play a central role in enhancing caspase-3 activity in M 4 N-treated cells, supplement of survivin-myc-His via overexpression should allow reversion of this trend. We performed experiments to test this. For the control, C3 cells were only treated with 40 M M 4 N, whereas other C3 cell samples were first transfected with the vector, Cdc2, or survivin before the 40 M 4 N treatment. Eight hours posttransfection, media were replaced with complete growth media containing the same M 4 N concentration. The activity of the control measured at 0.0315 of OD (405 nm) was set as the basal M 4 N-induced caspase-3 activity. Compared to the control, the caspase-3 activity in Cdc2-transfected cells and survivin-transfected cells was reduced by 36% and 54%, respectively, whereas transfection with the vector showed no effect on M 4 N-induced caspase-3 activity (Fig. 4B) .
We next investigated whether a C3 cell line stably expressing survivin-myc-His was even more resistant to M 4 N-induced apoptosis relative to C3 cells or C3 cells transiently transfected with survivin-myc-His. The survivin stable line was expanded from a single clone and expressed His-tagged survivin (Fig. 4C) . Cells of the stable line were treated with either 1% DMSO or 40 M of M 4 N for 3 days. Caspase-3 activity was measured every 5 min for 6 h to generate caspase-3 activity kinetics of these samples. During the linear portion of the graph, maximal activities occurred around 3 h after incubation of cell extracts with Ac-DEVD-pNA, at which time the caspase-3 activities of C3 cells transfected with survivin-myc-His and C3 cells stably expressing survivin-myc-His were compared. We found that M 4 N-induced caspase-3 activity in C3 cells was reduced by 50% and 75% in transiently and stably survivin-myc-His transfected cells, respectively (Fig. 4C) . The impact of M 4 N treatment on cell growth was not apparent before 24 h of treatment (Fig. 5A) . Following 2 days in media containing M 4 N, however, only the C3 cells transfected with the Cdc2 gene continued growth. Over the next 3 days, the number of these cells increased significantly, indicating that they were, at least partially, resistant to M 4 N effects. In contrast, those cells that were transfected with the pIRESpuro2 vector (pIRES), or only received FuGENE 6, ceased growth.
To specifically identify and quantitate those C3 cells spared from M 4 N-induced effects by exogenous supplementation of Cdc2, we characterized the recovery of M 4 N-treated C3 cells by cotransfection of a lacZ containing marker plasmid with the test plasmid pcDNA3.1-myc-His, containing Cdc2. Eight hours after transfection, the C3 cells were treated with 40 M M 4 N. After 2 days and 4 days following M 4 N treatment, the cells were fixed and stained with 5-bromo-4-chloro-3-indolyl ␤-D-galactoside for ␤-galactosidase expression. The cells carrying the transfected genes appeared dark blue under light microscope. In the case of the vector, the number of blue cells continued to decrease from day 2 to day 4 in the presence of M 4 N (presumably because both endogenous Cdc2 and survivin expression was down-regulated) (Fig. 5B) . In the case of the vector carrying the transfected Cdc2 gene, the number of blue cells increased by 37.1% from day 2 to day 4. This suggests that the added Cdc2 is able to reverse the M 4 N-induced cell-cycle arrest. We also tested whether the addition of survivin alone was able to protect M 4 N-arrested cells from progressing to cell death. The number of cells transfected with survivin as determined by lacZ staining remained nearly unchanged from day 2 to day 4 (a mere 2.4% increase), suggesting that addition of survivin alone does not reverse cell arrest, although these cells are protected from M 4 N-induced apoptosis (Fig. 5B) .
To determine whether Cdc2 localization is responsible for the recovery of C3 cell growth, we transiently transfected C3 cells with pcDNA3.1-Cdc2-myc-His. C3 cells treated with 40 M M 4 N were probed with monoclonal Cdc2 antibody; transfected cells treated with 1% DMSO or treated with 40 M M 4 N were probed with anti-His antibody. As expected, M 4 N treatment inhibited Cdc2 expression in nontransfected cells, and very little residual Cdc2 was present in the cytoplasm, but absent in the nucleus (Fig. 5C ). In the Cdc2-transfected cells, Cdc2 was expressed throughout the M 4 N-treated and untreated cell, indicating that CMV-driven Cdc2 overexpression was not affected by M 4 N treatment. In nondividing cells, Cdc2 was predominantly localized to the cytoplasm and only some to the nucleus. In dividing cells, brighter FITC staining of Cdc2-His was colocalized with chromosomes, indicating that transfected M 4 N-treated C3 cells had precise Cdc2 localization for normal growth (Fig. 5C ).
Discussion
In this study, we have shown that M 4 N treatment results in nuclear DNA cleavage, the formation of condensed nuclei and apoptotic bodies, and the activation of caspase-3, which are all hallmark features of apoptotic cells. We have shown further that M 4 N-induced apoptosis is mediated via the mitochondrial pathway but not the death-receptor pathway. More interestingly, it seems that M 4 N affects at least one of the regulators of apoptosis, survivin. We demonstrated in this study that M 4 N strongly suppresses survivin gene expression. This phenomenon is timedependent and occurs as early as 24 h post-M 4 N treatment, before the onset of significant caspase-3 activity and apoptosis (unpublished data). This finding suggests that survivin inhibition by M 4 N may occur before caspase-3 activation and apoptosis rather than a shutdown of survivin synthesis as a result of apoptosis.
Although the CMV promoter contains three putative Sp1 binding sites (27) , it has been shown that deletion of these elements does not have significant impact on CMV transcription and replication at high multiplicities of infection (28) . Because the CMV promoter can compensate for the loss of the Sp1 binding sites, the prevention of Sp1 binding to CMV promoter by M 4 N is likely inconsequential. However, both mouse and human Cdc2 and survivin endogenous genes require successful binding of Sp1 to their promoters to initiate transcription (17, 18, 29) . We observed that C3 cells transfected with Cdc2 and survivin, under the control of the CMV promoter, are resistant to M 4 N-mediated cell arrest or death. The discovery conforms to the model that the effect of M 4 N is selective to Sp1-dependent genes.
Phosphorylation on Thr-34 of survivin by p34 cdc2 (30) was found to be important for survivin protein stability. Survivin protein is degraded via the ubiquitin-proteasome pathway. In addition, an unphosphorylatable T34A survivin mutant has a faster turnover rate than the wild type (31) . This may explain why genetic inactivation (32) or pharmacological inhibition (33) of Cdc2 results in cell apoptosis. Such a cytoprotective role of Cdc2 was also observed in CMV-Cdc2-transfected cells. Phosphorylation of residual survivin protein left over in M 4 N-treated cells could have generated a more stable form of survivin, leading to the reduction of M 4 N-induced caspase-3 activity as observed (Fig. 4B) . It is therefore likely that the overexpressed Cdc2 phosphorylates residual survivin, which can become more stable before survivin transcription is inhibited by M 4 N. Further studies on this possibility will be conducted.
In the present study, we have demonstrated what appeared to be the dual effect of M 4 N in counteracting both the uncontrolled growth and the inactivated apoptosis in C3 transformed cells. The notion that M 4 N may be able to suppress other types of cancer in vivo by the same mechanism is further supported by our recent observation that five human tumor cell lines (MCF-7, breast; Hep3B, liver; HT-29, colorectal; LNCaP, prostate; K-562, leukemia) and their cancer xenografts in Thy Ϫ ͞Thy 
